Hatha Yoga Practices: Energy Expenditure, Respiratory Changes and Intensity of Exercise

The aim of this study was to critically observe the energy expenditure, exercise intensity and respiratory changes during a full yoga practice session. Oxygen consumption (V˙O2), carbon dioxide output (V˙CO2), pulmonary ventilation (V˙E), respiratory rate (Fr) and tidal volume (VT), were measured in 16 physical posture (asanas), five yoga breathing maneuvers (BM) and two types of meditation. Twenty male (age 27.3 ± 3.5 years, height 166.6 ± 5.4 cm and body weight 58.8 ± 9.6 kg) yoga instructors were studied. Their maximal oxygen consumption (V˙O2max) was recorded. The exercise intensity in asanas was expressed in percentage V˙O2max . In asanas, exercise intensity varied from 9.9 to 26.5% of V˙O2max . Highest energy cost was 3.02 kcal min−1. In BM highest V˙E was 53.7 ± 15.5 l min−1. VT was 0.97 ± 0.59, 1.41 ± 1.27 and 1.28 ± l/breath with corresponding Fr of 14.0 ± 5.3, 10.0 ± 6.35, 10.0 ± 5.8 breaths/min. Average energy expenditure in asanas, BM and meditation were 2.29, 1.91 and 1.37 kcal min−1, respectively. Metabolic rate was generally in the range of 1-2 metabolic equivalents (MET) except in three asanas where it was >2 MET. V˙O2 was 0.27 ± 0.05 and 0.24 ± 0.04 l min−1 in meditation and Shavasana, respectively. Although yogic practices are low intensity exercises within lactate threshold, physical performance improvement is possible owing to both better economy of breathing by BM and also by improvement in cardiovascular reserve. Other factors such as psycho-physiological and better relaxation may contribute to it

Applications of the non-dominated sorting genetic algorithm (NSGA) in chemical reaction engineering

Most of the chemical reaction engineering optimization problems encounters more than one objective functions. A considerable amount of research has been reported on the multiobjective optimization of various chemical reactors using various non-dominated sorting genetic algorithms. This is reviewed in this paper. The introduction of the topic is given at the beginning, followed by the description of multi-objective optimization and Pareto set. We have then discussed various non-dominated sorting genetic algorithms and its applications in chemical reaction engineering. Some comments are also made on the future research direction in this area

Oral clonidine: an effective adjuvant in functional endoscopic sinus surgery

Background: A comparative study to evaluate the efficacy of intravenous Dexmedetomidine as a hypotensive agent in comparison to oral Clonidine in Endoscopic Nasal Surgery or Functional Endoscopic Sinus Surgery (FESS).Methods: Forty patients ASA I or II scheduled for Endoscopic Nasal Surgery were equally randomly assigned to receive either dexmedetomidine 1μg/Kg over 10 min before induction of anesthesia followed by 0.5μg/Kg/h infusion during maintenance (Group D), or oral Clonidine (Group C) 2µg/kg with minimal water 1 hour prior starting of surgery. Rescue bolus doses of Propofol (10mg/dose) were given to maintain mean arterial blood pressure (MAP) between (50-70mmHg). General anesthesia was maintained with Isoflurane 1%-2%. The surgical field was assessed using Average Category Scale. Hemodynamic variables (MAP and HR) were recorded at 10 minutes interval.Results: Both group C and group D reached the desired MAP (50-70mmHg) with no intergroup differences in HR but a statistically significant lower MAP was noticed in group C. The quality of the surgical field in the range of MAP (50-70mmHg) were 2-3 as per average category Scale with significantly lower score in Group C. Mean intraoperative propofol consumption was significantly higher in group D than C group.Conclusions: Both Dexmedetomidine or oral clonidine with isoflurane are safe agents for controlled hypotension, but oral clonidine provides lower MAP and better surgical field. Compared with Dexmedetomidine, oral clonidine offers the advantage of less consumption of propofol

Dichlorido[μ-10,21-dimethyl-2,7,13,18-tetra­phenyl-3,6,14,17-tetra­aza­tricyclo­[17.3.1.18,12]tetra­cosa-1(23),2,6,8,10,12(24),13,17,19,21-deca­ene-23,24-diolato]dicopper(II) ethanol hemisolvate dihydrate

The dinuclear title complex, [Cu2(C46H38N4O2)Cl2]·0.5C2H5OH·2H2O, is located on crystallographic inversion centres with two half-mol­ecules in the asymmetric unit. The two CuII atoms are coordinated by a hexa­dentate dianionic ligand formed in situ from the condensation of two tridentate ligands by four imine N atoms and two bridging phenolate O atoms along with two Cl atoms at axial positions. The coordination geometry around the metal atoms is distorted square-pyramidal (τ = 0.185 and 0.199). The non-bonding Cu⋯Cu distances are 2.9556 (12) and 2.9506 (12) Å in the two dimers. The packing is stabilized through solvent-mediated inter­molecular O—H⋯O and O—H⋯Cl hydrogen bonds. The diamine chain of one of the dimers is disordered over two positions in a 0.680 (5):0.320 (5) ratio

Learning to Self-Manage by Intelligent Monitoring, Prediction and Intervention

Despite the growing prevalence of multimorbidities, current digital self-management approaches still prioritise single conditions. The future of out-of-hospital care requires researchers to expand their horizons; integrated assistive technologies should enable people to live their life well regardless of their chronic conditions. Yet, many of the current digital self-management technologies are not equipped to handle this problem. In this position paper, we suggest the solution for these issues is a model-aware and data-agnostic platform formed on the basis of a tailored self-management plan and three integral concepts - Monitoring (M) multiple information sources to empower Predictions (P) and trigger intelligent Interventions (I). Here we present our ideas for the formation of such a platform, and its potential impact on quality of life for sufferers of chronic conditions

A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113).

Funder: European Organisation for Research and Treatment of Cancer; FundRef: http://dx.doi.org/10.13039/501100004897Funder: Ligue Nationale de Lutte contre le Cancer (France)BACKGROUND: Uterine sarcomas are a group of rare tumors that include different subtypes. Patients with histopathological high-grade diseases are at high-risk of recurrence or progression, and have a poor prognosis. We aim to explore the most appropriate management in patients with uterine high-grade sarcomas. PRIMARY OBJECTIVE: To assess the efficacy of maintenance treatment with cabozantinib in patients with high-grade uterine sarcomas who achieved clinical benefit after standard chemotherapy. STUDY HYPOTHESIS: Maintenance treatment with cabozantinib after standard chemotherapy given as an adjuvant treatment after curative surgery, or in locally advanced or metastatic disease, increases progression-free survival compared with placebo TRIAL DESIGN: This is a randomized double blinded phase II trial. MAJOR INCLUSION/EXCLUSION CRITERIA: The study is enrolling adult patients with high-grade undifferentiated uterine sarcomas, high-grade endometrial stromal sarcomas, high-grade leiomyosarcoma, and high-grade adenosarcoma, FIGO (Federation International gynecologue Obstétricien) stage II/III to IV in stable disease or who achieved complete or partial response with doxorubicin ± ifosfamide, who are assigned 1:1 to 60 mg daily cabozantinib (experimental arm) or placebo (control arm), as maintenance therapy. Exclusion criteria include low-grade sarcoma. PRIMARY ENDPOINT: Progression-free survival at 4 months. SAMPLE SIZE: The study plans to enroll 90 patients to allow the randomization of 54 patients to detect an improvement in 4-month progression-free survival from 50% to 80% with 15% significance level and 85% power. Estimated dates for accrual completion: recruitment for the trial started in February 2015, and has currently enrolled 83 patients, of whom 35 patients have been randomized. The end of recruitment is anticipated for December 2020. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, number NCT01979393

Serials Spoken Here–Reports of Conferences, Institutes and Seminars

This quarter's column offers a report from the Acquisitions Institute at Timberline Lodge, held May 14–17, 2016, in Timberline Lodge, Oregon, and also provides coverage of multiple sessions from the Kraemer Copyright Conference, held June 6–7, 2016, in Colorado Springs, Colorado. Some reports are collected, as well, from the NASIG Annual Conference, held June 9–12, 2016, in Albuquerque, New Mexico, and the American Library Association (ALA) Annual Conference, held June 23–28, 2016, in Orlando, Florida. Lastly, there is a report from the International Federation of Library Associations and Institutions (IFLA) World Library and Information Congress, held August 13–19, 2016, in Columbus, Ohio. Topics covered include open access, linked data, copyright, text mining, e-resource management, and digitization

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown

TRANSITION PROBABILITY IN RESONANCE CONDITION FOR Z=110

The transition probability for different states are found out for the isotopes of z=110.The half-life are also calculated and it is seen that the stable form of isotope is A=281 ,z=11